Logo image of OTC.CA

OCUMETICS TECHNOLOGY CORP (OTC.CA) Stock Fundamental Analysis

TSX-V:OTC - TSX Venture Exchange - CA67577H1047 - Common Stock - Currency: CAD

0.305  +0.01 (+3.39%)

Fundamental Rating

1

Overall OTC gets a fundamental rating of 1 out of 10. We evaluated OTC against 16 industry peers in the Health Care Equipment & Supplies industry. While OTC seems to be doing ok healthwise, there are quite some concerns on its profitability. OTC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OTC has reported negative net income.
OTC had a negative operating cash flow in the past year.
OTC.CA Yearly Net Income VS EBIT VS OCF VS FCFOTC.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -1M -2M -3M

1.2 Ratios

The Return On Assets of OTC (-103.47%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -103.47%
ROE N/A
ROIC N/A
ROA(3y)-179.17%
ROA(5y)N/A
ROE(3y)-1432.94%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OTC.CA Yearly ROA, ROE, ROICOTC.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 -1K -2K -3K

1.3 Margins

OTC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OTC.CA Yearly Profit, Operating, Gross MarginsOTC.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, OTC has more shares outstanding
Compared to 1 year ago, OTC has a worse debt to assets ratio.
OTC.CA Yearly Shares OutstandingOTC.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 20M 40M 60M 80M 100M
OTC.CA Yearly Total Debt VS Total AssetsOTC.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 500K 1M 1.5M 2M 2.5M

2.2 Solvency

OTC has an Altman-Z score of -2.87. This is a bad value and indicates that OTC is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.87, OTC is in the better half of the industry, outperforming 62.50% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.87
ROIC/WACCN/A
WACCN/A
OTC.CA Yearly LT Debt VS Equity VS FCFOTC.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 1M -1M -2M

2.3 Liquidity

OTC has a Current Ratio of 11.37. This indicates that OTC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 11.37, OTC belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
OTC has a Quick Ratio of 11.37. This indicates that OTC is financially healthy and has no problem in meeting its short term obligations.
OTC has a better Quick ratio (11.37) than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 11.37
Quick Ratio 11.37
OTC.CA Yearly Current Assets VS Current LiabilitesOTC.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 500K 1M 1.5M

More info and screens

0

3. Growth

3.1 Past

OTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.96%, which is quite impressive.
EPS 1Y (TTM)32.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OTC.CA Price Earnings VS Forward Price EarningsOTC.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OTC.CA Per share dataOTC.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0 -0.01 -0.01 -0.02

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

OTC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OCUMETICS TECHNOLOGY CORP

TSX-V:OTC (5/8/2025, 7:00:00 PM)

0.305

+0.01 (+3.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners46.05%
Ins Owner ChangeN/A
Market Cap36.53M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -103.47%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-179.17%
ROA(5y)N/A
ROE(3y)-1432.94%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 75.73%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.37
Quick Ratio 11.37
Altman-Z -2.87
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)111.79%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y36.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-29.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.42%
OCF growth 3YN/A
OCF growth 5YN/A